- Arena Pharmaceuticals has an impressive pipeline of compounds, and its trials are progressing well now, despite the impact of COVID-19.
- After its equity offering in early June at $50 per share, shares topped $60 and have not looked back. The 52-week high of $86.48 was set on the 12th.
- Based on its catalyst timeline, H1 2021 will experience a lull compared to the second half. While awaiting catalysts, potential investors may want to consider building a position.
For further details see:
Arena Pharmaceuticals: H1 2021 Is A Good Time To Consider The Stock Again